PharmiWeb.com - Global Pharma News & Resources

Biotech - Press Releases

Date Title Company
26-Dec-2022 CRISPR Off-Target Analysis Now Available with CD Genomics’ Bioinformatics-Analysis Platform CD Genomics
26-Dec-2022 CD Genomics RNA-Solutions Platform Unveils m7G MeRIP Sequencing for Scientific Research CD Genomics
23-Dec-2022 Profacgen Enhanced Its CLIP-Seq Service for RNA-Protein Interaction Research Profacgen
23-Dec-2022 Alfa Chemistry Enriches API Supply by Adding Lenalidomide, Parecoxib Sodium, and Rivaroxaban Alfa Chemistry
23-Dec-2022 CD Formulation Launches One-stop OEM/ODM and Analytical Testing Solutions for Cosmetics CD Formulation
23-Dec-2022 Nearly 480 Cosmetic Ingredients Are Now Available at CD Formulation CD Formulation
20-Dec-2022 Novotech is Gold Sponsor at Biotech Showcase 2023 Novotech Health Holdings Pte Ltd
16-Dec-2022 Ori Biotech and Inceptor Bio partner to accelerate solid tumor cell therapy access Ori Biotech
15-Dec-2022 Data Shows 50% of New Trials Have Sites in Asia Pacific Novotech Health Holdings Pte Ltd
15-Dec-2022 Electroducer announces the publication of positive results from its pilot study in EuroIntervention medical journal Andrew Lloyd Associates
15-Dec-2022 Fujifilm Invests in PhenoVista Biosciences from its Life Sciences Corporate Venture Capital Fund Fujifilm
15-Dec-2022 Creative BioMart Launched an Integrated Neuroscience Technology Platform Creative BioMart
15-Dec-2022 Preventing Strokes and Heart Attacks Doesn't Have to Come with the Risk of Life-threatening Bleeding Verseon International Corporation
14-Dec-2022 Conference Co-chairs from Merck & AstraZeneca invitation to join 3D Cell Culture  SAE Media Group
14-Dec-2022 Biocomposites announces year of record sales and company growth Biocomposites
14-Dec-2022 PrecisionLife Enters into a Multi Target R&D Collaboration Agreement with Ono Pharmaceutical PrecisionLife
14-Dec-2022 Quartic.ai Addresses Process Development Capacity Constraints with AI-Powered PD Optimization Quartic.ai
14-Dec-2022 Ribonexus appoints Steven Powell as CEO Andrew Lloyd Associates
14-Dec-2022 Etcembly Announces Breakthrough in Optimising TCR Assets Etcembly
13-Dec-2022 Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination With KEYTRUDA® (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial Moderna